<DOC>
	<DOCNO>NCT01338545</DOCNO>
	<brief_summary>This observational study evaluate dosage pattern , safety efficacy RoActemra/Actemra ( tocilizumab ) clinical practice patient moderate severe rheumatoid arthritis respond intolerant least one disease-modifying antirheumatic drug ( DMARD ) TNF inhibitor . Data collect patient 12 month .</brief_summary>
	<brief_title>An Observational Study Dosage Patterns Routine Clinical Practice Patients With Rheumatoid Arthritis ( ACT-LIFE )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Moderate severe rheumatoid arthritis ( RA ) least 6 month duration Nonresponder intolerant least one DMARD TNF inhibitor treatment Initiated treatment RoActemra accord Summary Product Characteristics ( SPC ) indication History autoimmune disease joint inflammatory disease RA Pregnant lactate woman Patients start RoActemra treatment clinical trial compassionate use Treatment investigational drug previous 4 week ( least 5 time halflife drug )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>